Publications by authors named "F Ajana"
Article Synopsis
- * Liver injury from COVID-19 results from multiple factors, including systemic inflammation, small vessel blood clots, reduced blood flow to the liver, and possible drug side effects, rather than direct infection of liver cells.
- * A case study is highlighted involving a 25-year-old man who was admitted for abdominal pain and exhibited acute severe liver failure before showing any respiratory symptoms associated with COVID-19.
Article Synopsis
- - A 25-year-old patient with a history of unprotected sex developed cholestatic jaundice and severe itching for two months, leading to an examination that revealed intense jaundice and swollen lymph nodes.
- - Imaging showed edema and lymphadenopathy, while blood tests indicated significant liver enzyme elevation and negative viral serologies, prompting further testing for syphilis, which returned positive.
- - A liver biopsy confirmed syphilitic hepatitis, resulting in treatment with ceftriaxone, which led to remarkable improvement within 48 hours.
Polysplenia syndrome (PSS) is a rare congenital disease that associates multiple spleens to other malformations, most frequently cardiac, vascular, visceral, and biliary malformations. Most patients with PSS die in the early neonatal period because the disease is often accompanied by serve cardiac and biliary abnormalities. However, some patients have only mild cardiovascular malformations or anomalies in the abdominal organs, which are typically diagnosed incidentally in adulthood.
View Article and Find Full Text PDFThe macrophage activation syndrome (MAS) is a rare but potentially fatal disease. We report two cases of Crohn´s disease, one under 5-aminosalicylic acid and the other under corticosteroid, having developed MAS. The first was a male patient hospitalized for high fever, clinical examination found fever and left inguinal lymph node.
View Article and Find Full Text PDFBackground: Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown. We hypothesized that once-daily dolutegravir/tenofovir/emtricitabine could reduce the viral reservoir through rapid viral replication control further than once-daily darunavir/cobicistat/tenofovir/emtricitabine.
Methods: The OPTIPRIM2-ANRS 169 study was a randomized (1:1), open-label, multicentre trial in adults with ≤5 or ≤3 HIV antibodies detected, respectively, by western blot or immunoblot in the last 10 days.